Tufts, Saama set out to ‘optimize’ clinical development via research tie-up
The clinical data analytics company Saama Technologies is collaborating with researchers from the Tufts Center for the Study of Drug Development (Tufts CSDD) at Tufts University School of Medicine.
Saama Chief Strategy Officer Sagar Anisingaraju said the hope is to garner a better understanding of and new insights regarding the use and effect of automation and artificial intelligence (AI) powered technologies when applied to research and development (R&D).
“We also want to identify technology solutions that can address pain points related to clinical development, in order to help companies address them through future digital transformation development programs,” he told us.
Saama and Tufts CSDD will conduct an executive roundtable this fall and conduct a global, industry-wide survey.
The research looks to ascertain which areas of the R&D process the industry believes could most easily be automated, and will assess industry adoption, challenges, and concerns from both the sponsor and contract research organization (CRO) perspective.
“We are confident that our approach of combining both qualitative and quantitative research will yield informative and compelling results that can be leveraged to help optimize clinical development,” Anisingaraju said.
“Ultimately, our organizations want to help make safe and effective new therapies available to the physicians who treat and the patients who experience medical conditions.”
Earlier this year, Saama closed a $40m financing round, bringing its total funds raised since 2015 to $75m. The company’s platform is powered by AI to support clinical trial design and conduct across various development stages.
